Immunic (NASDAQ:IMUX) Given New $8.00 Price Target at D. Boral Capital

Immunic (NASDAQ:IMUX) had its price target decreased by equities research analysts at D. Boral Capital from $10.00 to $8.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Several other equities analysts also recently commented on IMUX. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Friday, September 26th. Chardan Capital initiated coverage on Immunic in a research note on Monday, September 29th. They issued a “buy” rating and a $13.00 price target for the company. Roth Capital assumed coverage on Immunic in a report on Friday, November 7th. They set a “buy” rating and a $3.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Immunic has an average rating of “Moderate Buy” and an average target price of $7.80.

Immunic Stock Performance

Shares of Immunic stock traded down $0.04 during trading on Thursday, reaching $0.72. 905,740 shares of the company’s stock were exchanged, compared to its average volume of 1,287,279. The firm’s 50-day moving average price is $0.83 and its 200 day moving average price is $0.87. The company has a market cap of $71.42 million, a P/E ratio of -0.77 and a beta of 1.53. Immunic has a 1-year low of $0.56 and a 1-year high of $1.42.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. As a group, equities research analysts predict that Immunic will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently added to or reduced their stakes in the stock. HB Wealth Management LLC purchased a new stake in Immunic during the third quarter worth about $81,000. GSA Capital Partners LLP purchased a new stake in shares of Immunic during the 3rd quarter worth approximately $170,000. Jane Street Group LLC raised its holdings in shares of Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after purchasing an additional 152,726 shares during the period. 683 Capital Management LLC raised its holdings in shares of Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after purchasing an additional 200,000 shares during the period. Finally, Aberdeen Group plc purchased a new position in Immunic in the first quarter valued at approximately $1,155,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.